Alkermes plc - Ordinary Shares (ALKS): Price and Financial Metrics


Alkermes plc - Ordinary Shares (ALKS): $24.00

-0.32 (-1.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ALKS POWR Grades


  • Growth is the dimension where ALKS ranks best; there it ranks ahead of 96.25% of US stocks.
  • The strongest trend for ALKS is in Growth, which has been heading down over the past 163 days.
  • ALKS's current lowest rank is in the Momentum metric (where it is better than 9.38% of US stocks).

ALKS Stock Summary

  • Alkermes plc's stock had its IPO on July 16, 1991, making it an older stock than 83.16% of US equities in our set.
  • Price to trailing twelve month operating cash flow for ALKS is currently 28.49, higher than 82.15% of US stocks with positive operating cash flow.
  • As for revenue growth, note that ALKS's revenue has grown -3.6% over the past 12 months; that beats the revenue growth of just 18.74% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Alkermes plc are DAIO, RMED, SWIR, TMDX, and INSM.
  • ALKS's SEC filings can be seen here. And to visit Alkermes plc's official web site, go to www.alkermes.com.

ALKS Valuation Summary

  • In comparison to the median Healthcare stock, ALKS's EV/EBIT ratio is 519.45% lower, now standing at -122.9.
  • Over the past 243 months, ALKS's EV/EBIT ratio has gone down 53.7.
  • ALKS's price/sales ratio has moved down 32.4 over the prior 243 months.

Below are key valuation metrics over time for ALKS.

Stock Date P/S P/B P/E EV/EBIT
ALKS 2021-08-31 4.6 4.6 -80.3 -122.9
ALKS 2021-08-30 4.6 4.6 -80.7 -123.4
ALKS 2021-08-27 4.6 4.6 -79.9 -122.3
ALKS 2021-08-26 4.5 4.5 -78.4 -120.1
ALKS 2021-08-25 4.5 4.5 -78.7 -120.6
ALKS 2021-08-24 4.5 4.5 -78.0 -119.5

ALKS Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at 8.37%.
  • Its 4 year cash and equivalents growth rate is now at -11.96%.
  • Its 5 year price growth rate is now at -65.14%.
ALKS's revenue has moved up $505,388,000 over the prior 67 months.

The table below shows ALKS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 1,129.283 138.037 -91.684
2021-06-30 1,100.154 115.463 -62.83
2021-03-31 1,043.966 77.968 -94.625
2020-12-31 1,038.756 82.842 -110.861
2020-09-30 1,171.491 57.569 -73.573
2020-06-30 1,161.722 28.338 -126.317

ALKS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALKS has a Quality Grade of B, ranking ahead of 88.71% of graded US stocks.
  • ALKS's asset turnover comes in at 0.582 -- ranking 63rd of 680 Pharmaceutical Products stocks.
  • OTLK, AVEO, and LXRX are the stocks whose asset turnover ratios are most correlated with ALKS.

The table below shows ALKS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.582 0.835 -0.047
2021-06-30 0.576 0.836 -0.029
2021-03-31 0.556 0.835 -0.050
2020-12-31 0.557 0.828 -0.061
2020-09-30 0.641 0.845 -0.034
2020-06-30 0.646 0.844 -0.076

ALKS Price Target

For more insight on analysts targets of ALKS, see our ALKS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.50 Average Broker Recommendation 1.88 (Hold)

ALKS Stock Price Chart Interactive Chart >

Price chart for ALKS

ALKS Price/Volume Stats

Current price $24.00 52-week high $33.00
Prev. close $24.32 52-week low $18.02
Day low $23.52 Volume 1,972,200
Day high $24.50 Avg. volume 1,283,050
50-day MA $23.37 Dividend yield N/A
200-day MA $25.69 Market Cap 3.88B

Alkermes plc - Ordinary Shares (ALKS) Company Bio


Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 and is based in Dublin, Ireland.


ALKS Latest News Stream


Event/Time News Detail
Loading, please wait...

ALKS Latest Social Stream


Loading social stream, please wait...

View Full ALKS Social Stream

Latest ALKS News From Around the Web

Below are the latest news stories about Alkermes plc that investors may wish to consider to help them evaluate ALKS as an investment opportunity.

BioDelivery (BDSI) Stock Up on Raised Guidance for 2021

BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.

Yahoo | January 21, 2022

Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate

Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.

Yahoo | January 21, 2022

ChemoCentryx (CCXI) Tavneos Gets EU Nod for ANCA Vasculitis

Following approval in the EU, ChemoCentryx (CCXI) plans to launch Tavneos for treating ANCA-associated vasculitis in first-half 2022.

Yahoo | January 20, 2022

Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB

Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.

Yahoo | January 20, 2022

Regeneron (REGN)/Sanofi's Libtayo sBLA Accepted by the FDA

Regeneron (REGN) sBLA seeking label expansion of Libtayo in combination with chemotherapy as first-line treatment in advanced lung cancer accepted by the FDA.

Yahoo | January 20, 2022

Read More 'ALKS' Stories Here

ALKS Price Returns

1-mo N/A
3-mo -23.83%
6-mo -6.87%
1-year 8.16%
3-year -29.56%
5-year -56.88%
YTD 3.18%
2021 16.59%
2020 -2.21%
2019 -30.87%
2018 -46.08%
2017 -1.53%

Continue Researching ALKS

Want to see what other sources are saying about Alkermes plc's financials and stock price? Try the links below:

Alkermes plc (ALKS) Stock Price | Nasdaq
Alkermes plc (ALKS) Stock Quote, History and News - Yahoo Finance
Alkermes plc (ALKS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8002 seconds.